-
公开(公告)号：EP1040836A4
公开(公告)日：2004-11-10
申请号：EP98959165
申请日：1998-12-11
发明人： KAWAMURA IKUO , OHTA MARIKO , TAKESHITA SHIGERU
IPC分类号： A61K38/30 , A61K31/435 , A61K38/13
CPC分类号： A61K38/30 , Y10S514/893 , Y10S930/12 , A61K2300/00
摘要： Immunosuppressant agonists containing as the active ingredient insulin-like growth factor I or analogs thereof. Insulin-like growth factor I-producing agents containing as the active ingredient macrolide compounds having an immunosuppressive effect. Drugs promoting bile secretion, drugs promoting bile acid secretion and/or remedies for biliary stasis containing as the active ingredient compounds having an insulin-like growth factor-producing effect.
-
公开(公告)号：EP1469854A1
公开(公告)日：2004-10-27
申请号：EP03703053.3
申请日：2003-01-27
发明人： ISHIDA, Junya,c/o Fujisawa Pharmaceut. Co., Ltd. , HATTORI, Kouji,c/o Fujisawa Pharmaceut. Co., Ltd. , KIDO, Yoshiyuki,c/o Fujisawa Pharmaceut. Co., Ltd , YAMAMOTO, Hirofumi,c/o Fujisawa Pharmac. Co. Ltd.
IPC分类号： A61K31/519 , A61K31/502 , A61K31/4725 , C07D239/88 , C07D495/04 , C07D471/04 , C07D491/04 , C07D401/06 , C07D237/32 , C07D217/24 , A61K31/517
CPC分类号： C07D401/06 , A61K31/4725 , A61K31/502 , A61K31/517 , A61K31/519 , C07D237/32 , C07D239/90 , C07D471/04 , C07D491/04 , C07D495/04
摘要： A condensed heterocyclic compound having poly(adenosine 5'-diphospho-ribose)polymerase (PARP) inhibitory activity represented by the formula (I): wherein R1 is hydrogen, halogen, lower alkyl or lower alkoxy, A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, etc, -Y1=Y2- is formula (II) wherein L11, L12, L13 and L14 is (1) lower alkylene, (2) lower alkenylene, etc, and R21, R22 , R23 and R24 is (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s), etc. provided that when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, then -Y1=Y2- is formula (III) or its prodrug, or their salts.
摘要翻译： 式（I）所示的具有聚（腺苷5'-二磷酸核糖）聚合酶（PARP）抑制活性的稠合杂环化合物：其中R1为氢，卤素，低级烷基或低级烷氧基，A和两个相邻的碳原子 其中L11，L12，L13和L14是（1）低级亚烷基，（2）低级亚烯基等的式（II）-Y1 = Y2-是与A形式苯环，吡啶环等键合的六元环， 并且R21，R22，R23和R24是（1）环状氨基，其被任选被一个或多个合适的取代基取代的苯基等取代，条件是当A和六元环的两个相邻碳原子与 与A型苯环键合，则-Y1 = Y2-为式（III）或其前药或其盐。
-
公开(公告)号：EP1441732A2
公开(公告)日：2004-08-04
申请号：EP02802729.0
申请日：2002-11-08
发明人： TSUTSUMI, Hideo,Fujisawa Pharmaceutic. Co., Ltd. , TABUCHI, Seiichiro,Fujisawa Pharmaceuti. Co.Ltd. , AKAHANE, Atsushi,Fujisawa Pharmaceutic. Co., Ltd , YASUDA, Hironobu,Fujisawa Pharmaceutic. Co.,Ltd. , OMORI, Hiroki,Fujisawa Pharmaceutic. Co., Ltd. , TEMMARU, KiyoshiFujisawa Pharmaceutic. Co., Ltd. , ZANKA, Atsuhiko,Fujisawa Pharmaceutic. Co., Ltd.
IPC分类号： A61K31/501 , C07D417/04 , C07D417/14 , C07D237/16 , A61P25/00
CPC分类号： C07D233/56 , C07D231/12 , C07D249/08 , C07D417/04 , C07D417/14
摘要： A thiazole derivative of the formula (I):wherein R is 1-optiona lly substituted-6-oxo-1,6-dihydro-3-pyridazinyl, R' is an optionally substituted phenyl, and R2 is hydrogen, a group of the formula (i): wherein R4 is hydrogen, lower alkyl or lower alkenyl, and R5 is hydrogen, optionally substituted lower alkyl, acyl, cyclo(lower)alkyl, lower alkenyl, optionally substituted aryl or heterocyclic, or a group of the formula (ii): wherein X is oxygen or sulfur, R8 is hydrogen or lower alkyl, R9 is hydrogen, optionally substituted lower alkyl, cyclo(lower)alkyl, lower alkoxy or mono- or di-lower alkylamino or R?8 and R9¿ may be combine together to form optionally substituted saturated N-containing heterocyclic, or a salt thereof._The compounds are useful as Adenosine antagonists. The application also discloses an improved process for the preparation of pyridazinones (XII-1)
-
公开(公告)号：EP1341553A4
公开(公告)日：2004-07-28
申请号：EP01995504
申请日：2001-12-14
发明人： TSO J YUN , HINTON PAUL , VASQUEZ MAXIMILIANO , TAMURA KOUICHI , HIGASHI YASUYUKI , SEKI NOBU , UEDA HIROTSUGU
IPC分类号： C12N15/09 , A61K39/00 , A61K39/395 , A61K45/00 , A61P37/00 , A61P37/06 , A61P41/00 , A61P43/00 , C07K16/28 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , C12N15/00 , C12N15/12 , C12N15/13
CPC分类号： C07K16/2818 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2319/00
-
15.发明授权
公开(公告)号：EP0807105B1
公开(公告)日：2004-06-16
申请号：EP95935563.7
申请日：1995-10-25
发明人： OKU, Teruo , KAYAKIRI, Hiroshi , SATOH, Shigeki , ABE, Yoshito , SAWADA, Yuki , INOUE, Takayuki , TANAKA, Hirokazu
IPC分类号： C07D215/16 , A61K31/47 , C07D471/02 , A61K31/395 , C07D215/26 , C07D471/04
CPC分类号： C07D401/12 , C07D215/26 , C07D215/40 , C07D215/42 , C07D215/48 , C07D241/40 , C07D401/14 , C07D403/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
-
公开(公告)号：EP1365033A4
公开(公告)日：2004-04-07
申请号：EP02701664
申请日：2002-03-01
发明人： MANO HIROYUKI
CPC分类号： G01N33/57426 , C12Q1/6837 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： A method of examining chronic myelogenous leukemia characterized by measuring the expression level of a gene selected from the group consisting of IFIT-2 gene, LAGE-1 gene, BAGE gene, DDB1 gene, ETS2 gene, PIASy gene, PIASx-α gene, PIASx-β gene and DAPK3 gene in a test tissue or test cells, or determining the expression profile of a group of genes involving any of these genes.
-
17.发明授权Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists 失效Thiazolylbenzofuran衍生物及其作为SRS-A和白三烯拮抗剂的用途
公开(公告)号：EP1170009B1
公开(公告)日：2004-04-07
申请号：EP01123263.4
申请日：1997-01-17
发明人： Matsuo, Masaaki , Okumura, Kazuo , Shigenaga, Shinji , Nishimura, Hiroaki , Matsuda, Hiroshi , Hagiwara, Daijiro , Terasaka, Tadashi
IPC分类号： A61K31/427 , A61P29/00 , A61P37/08
CPC分类号： C07D417/04 , C07D417/14
-
公开(公告)号：EP1383760A1
公开(公告)日：2004-01-28
申请号：EP02714555.6
申请日：2002-04-09
发明人： TAKASUGI, Hisashi,Fujisawa Pharmaceutical Co. Ltd , TERASAWA, Takeshi,Fujisawa Pharmaceutical Co. Ltd , INOUE, Yoshikazu,Fujisawa Pharmaceutical Co. Ltd , NAKAMURA, Hideko,Fujisawa Pharmaceutical Co. Ltd , NAGAYOSHI, Akira,Fujisawa Pharmaceutical Co. Ltd , FURUKAWA, Yoshiro,Daiso Co. Ltd , MIKAMI, Masafumi,Daiso Co. Ltd , HINOUE, Kazumasa,Daiso Co. Ltd , OHTSUBO, Makoto,Daiso Co. Ltd
IPC分类号： C07D401/06 , C07D403/06 , C07D403/14 , C07D413/06 , A61K31/395 , A61P3/06
CPC分类号： C07D207/335 , C07C271/24 , C07C2601/10 , C07C2602/08 , C07D209/44 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/50 , C07D213/56 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/81 , C07D217/04 , C07D217/18 , C07D217/20 , C07D233/64 , C07D239/26 , C07D239/42 , C07D249/08 , C07D277/24 , C07D277/28 , C07D277/40 , C07D277/46 , C07D277/48 , C07D295/033 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/192 , C07D295/205 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/06 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The present invention relates to compounds of the formula (I) wherein X1 is wherein R?1, R2 and R10¿ are independently hydrogen or a suitable substituent; R?11 and R12¿ are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or -NH-; X2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is -(CH¿2?)n-, -CO-(CH2)m-, -CH=CH- or -CO-NH-, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.
摘要翻译： 本发明涉及式（I）化合物，其中X 1是其中R 1，R 2和R 10独立地是氢或合适的取代基; R 11和R 12独立地是氢或合适的取代基; R是不饱和的5至6元杂单环基团; A是直接键或-NH-; X 2是单环亚芳基，不饱和5至6元杂单环基或环亚烯基; Y是选自乙烯，三亚甲基和亚乙烯基的二价基团，其中CH 2任选地被NH或O取代，CH任选地被N替代; Z为 - （CH 2）n - ， - CO - （CH 2）m - ， - CH = CH-或-CO-NH-，其中n为1,2或3，m为1或2， 。 本发明的化合物抑制载脂蛋白B（Apo B）分泌，并且可用作预防和治疗由ApoB升高的循环水平引起的疾病或病症的药物。
-
公开(公告)号：EP1366066A2
公开(公告)日：2003-12-03
申请号：EP02703926.2
申请日：2002-03-07
发明人： TODA, Ayako,Fujisawa Pharmaceutical Co., Ltd , MIZUNO, Hiroaki,Fujisawa Pharmaceutical Co., Ltd , MATSUYA, Takahiro,Fujisawa Pharmaceutical Co. Ltd , MATSUDA, Hiroshi,Fujisawa Pharmaceutical Co. Ltd , MURANO, Kenji,Fujisawa Pharmaceutical Co. Ltd , BARRETT, David,Fujisawa Pharmaceutical Co. Ltd , OGINO, Takashi,Fujisawa Pharmaceutical Co. Ltd , MATSUDA, Keiji,Fujisawa Pharmaceutical Co. Ltd
摘要： This invention relates to new polypeptide compound represented by the following general formula (I): wherein R?1, R2, R3, R4, R5 and R6¿ are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1, 3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
-
公开(公告)号：EP1365021A1
公开(公告)日：2003-11-26
申请号：EP02700571.9
申请日：2002-02-08
发明人： MIYOSHI, S., c/o Fujisawa Pharmaceutical Co., Ltd. , OHKUBO, A., c/o Fujisawa Pharmaceutical Co., Ltd. , MORIKAWA, N., c/o Fujisawa Pharmaceutical Co., Ltd , OGAWA, Y., c/o Fujisawa Pharmaceutical Co., Ltd. , NISHIMURA,S., c/o Fujisawa Pharmaceutical Co., Ltd , FUKAGAWA, M., c/o Fujisawa Pharmaceutical Co., Ltd , ARAKAWA, H., c/o Fujisawa Pharmaceutical Co.,Ltd. , ZENKOU, Jyunko , SATO,Susumu, c/o Fujisawa Pharmaceutical Co., Ltd.
摘要： A method of highly efficiently transferring various selected molecules into various cells and a method of fusing cells. Cells and/or selected molecules such as polynucleotide are treated with cold gas plasma to thereby transfer the selected molecules located around cells into the cells, or cells are fused by treating the cells with cold gas plasma. Moreover, an apparatus for transferring selected molecules or fusing cells having a cold gas plasma generation unit for transferring selected molecules into cells is provided.
摘要翻译： 将各种选择的分子高效转移到各种细胞中的方法以及融合细胞的方法。 用冷气体等离子体处理细胞和/或选择的分子，例如多核苷酸，从而将位于细胞周围的选定分子转移到细胞中，或者通过用冷气体等离子体处理细胞来融合细胞。 此外，提供了用于转移所选择的分子或具有用于将选定分子转移到细胞中的具有冷气体等离子体产生单元的融合电池的装置。
-
-
-
-
-
-
-
-
-
搜索结果
1506 条记录 (耗时 0.039 秒)
